Business Description
Lepu Biopharma Co Ltd
ISIN : CNE100004SM4
Share Class Description:
HKSE:02157: Class HTotal Employee Number:
710Compare
Compare
Traded in other countries / regions
02157.Hong Kong Index Membership
Hong Kong Stock Connect IPO Date
2022-02-23Description
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.9 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.77 | |||||
Debt-to-EBITDA | 3.69 | |||||
Interest Coverage | 3.36 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.02 | |||||
Beneish M-Score | -0.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 276.7 | |||||
3-Year EPS without NRI Growth Rate | 67.6 | |||||
3-Year FCF Growth Rate | 41.1 | |||||
3-Year Book Growth Rate | 11.9 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.75 | |||||
9-Day RSI | 63.74 | |||||
14-Day RSI | 59.46 | |||||
3-1 Month Momentum % | -15.96 | |||||
6-1 Month Momentum % | -7.02 | |||||
12-1 Month Momentum % | -52.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.98 | |||||
Quick Ratio | 0.94 | |||||
Cash Ratio | 0.83 | |||||
Days Inventory | 163.72 | |||||
Days Sales Outstanding | 20.98 | |||||
Days Payable | 866.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.8 | |||||
Shareholder Yield % | -8.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 90.4 | |||||
Operating Margin % | 10.11 | |||||
Net Margin % | 28.06 | |||||
EBITDA Margin % | 31.01 | |||||
FCF Margin % | -14.12 | |||||
OCF Margin % | -1.37 | |||||
ROE % | 27.93 | |||||
ROA % | 10.24 | |||||
ROIC % | 3.89 | |||||
3-Year ROIIC % | 121.35 | |||||
ROC (Joel Greenblatt) % | 29.87 | |||||
ROCE % | 19.79 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 28.01 | |||||
Price-to-Owner-Earnings | 50.53 | |||||
PS Ratio | 7.95 | |||||
PB Ratio | 5.47 | |||||
Price-to-Tangible-Book | 9.49 | |||||
EV-to-EBIT | 26.64 | |||||
EV-to-EBITDA | 26.64 | |||||
EV-to-Revenue | 8.26 | |||||
EV-to-FCF | -58.51 | |||||
Price-to-GF-Value | 0.3 | |||||
Earnings Yield (Greenblatt) % | 3.75 | |||||
FCF Yield % | -1.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lepu Biopharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 1,027.337 | ||
| EPS (TTM) (HK$) | 0.166 | ||
| Beta | 1.952 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 41.03 | ||
| 14-Day RSI | 59.46 | ||
| 14-Day ATR (HK$) | 0.297047 | ||
| 20-Day SMA (HK$) | 4.51925 | ||
| 12-1 Month Momentum % | -52.65 | ||
| 52-Week Range (HK$) | 3.55 - 10.5 | ||
| Shares Outstanding (Mil) | 1,804.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lepu Biopharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lepu Biopharma Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lepu Biopharma Co Ltd Frequently Asked Questions
What is Lepu Biopharma Co Ltd(HKSE:02157)'s stock price today?
The current price of HKSE:02157 is HK$4.65. The 52 week high of HKSE:02157 is HK$10.50 and 52 week low is HK$3.55.
When is next earnings date of Lepu Biopharma Co Ltd(HKSE:02157)?
The next earnings date of Lepu Biopharma Co Ltd(HKSE:02157) is .
Does Lepu Biopharma Co Ltd(HKSE:02157) pay dividends? If so, how much?
Lepu Biopharma Co Ltd(HKSE:02157) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Lepu Biopharma Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers